Bundang CHA Medical Center
Seongnam-si, Gyeonggi-do, South Korea
NCT Number: NCT01385865
The purpose of this study is to evaluate the effect of mulberry leaf extract on blood glucose in subjects with impaired fasting glucose.
Looking for future studies?
Notify Me20 year and older
All sexes
Interventional
Not applicable
Seongnam-si, Gyeonggi-do, South Korea
The purpose of this study is to evaluate the effect of mulberry leaf extract on blood glucose in subjects with impaired fasting glucose. After 2 weeks run-in period for wash-out, subjects will randomly assigned to two groups, i.e. control group (placebo) or mulberry leaf extract group. They will intake placebo or mulberry leaf extract for 4 weeks. Biomarkers will be analyzed in blood samples in 0 and 4 weeks.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
18 tablets/day (6 tablets/serving x 3servings/day, mulberry leaf extract 336mg/1 tablet (800mg), 1-Deoxynojirimycin 4.3mg/1 g mulberry leaf extract), Duration: 4 weeks
18 tablets/day (6 tablets/serving x 3servings/day, lactose 511mg/1 tablet (650mg)), Duration: 4 weeks
Time frame: 0wk
Time frame: 4wk
Time frame: 0, 4 wk
Time frame: 0, 4 wk
Time frame: 0, 4wk
Time frame: 0, 4wk
Time frame: 0, 4wk
Time frame: 0, 4wk
Time frame: 0, 4wk
Time frame: 0, 4wk
Time frame: 0, 4wk
Ewha Womans University
Other
Effect of Mulberry Leaf Extract on Blood Glucose in Subjects With Impaired Fasting Glucose
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05887791
Diabetes Mellitus, Endocrine System Diseases
Esslingen am Neckar, Germany
View Trial DetailsNCT06471569
Behavior, Body Weight
Durham, North Carolina, United States
View Trial DetailsNCT06195566
Body Weight, Diabetes Mellitus
Riga, Latvia
View Trial DetailsNCT05724134
Body Weight, Diabetes Mellitus
New York, United States
View Trial Details